Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Fou...
November 13 2017 - 7:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a chemistry-driven
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that it
plans to report its financial results for its fiscal fourth quarter
and year ended September 30, 2017, after the U.S. markets close on
November 20, 2017. Enanta management will host a conference call at
4:30 p.m. ET to discuss these results and provide an update on
Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855)
840-0595 in the U.S. or (518) 444-4814 for international callers. A
replay of the conference call will be available starting at
approximately 7:30 p.m. ET on November 20, 2017, through 11:59 p.m.
ET on November 23, 2017 by dialing (855) 859-2056 from the U.S. or
(404) 537-3406 for international callers. The passcode for both the
live call and the replay is 6197609. A live audio webcast of the
call and replay can be accessed by visiting the “Events and
Presentation” section on the “Investors” page of Enanta’s website
at www.enanta.com.
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease
inhibitors, paritaprevir and glecaprevir, discovered and developed
through Enanta’s collaboration with AbbVie, have now been approved
in jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the U.S.-marketed regimens MAVYRET™
(glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir).
Royalties and milestone payments from the AbbVie collaboration
are helping to fund Enanta’s research and development efforts,
which are currently focused on the following disease targets:
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), respiratory syncytial virus (RSV) and hepatitis B virus
(HBV). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171113005560/en/
Investor:Enanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024